CREATING TRANSFORMATIVE
GENE-BASED MEDICINES
CREATING TRANSFORMATIVE
GENE-BASED Medicines
CREATING TRANSFORMATIVE
GENE-BASED MEDICINES
We are the leaders in the development of novel hSynC-based cell therapies and seek to create transformative treatments for unaddressed or under-addressed human genetic diseases.
IN PARTNERSHIP WITH
About US
Our mission: At CG Bioengineering, we are developing a human synthetic chromosome (hSynC) - Cell Engineering System with the aim of finding cures for people suffering from under-addressed and unaddressed human genetic diseases.
Our mission: At CG Bioengineering, we are developing a human synthetic chromosome (hSynC) - Cell Engineering System with the aim of finding cures for people suffering from under-addressed and unaddressed human genetic diseases.
Our Genetic Operating System:
Built upon over 20 Years Experience to Create
Transformative Synthetic Biology Medicines
01
Early 2000’s
Version 1.0 of a synthetic chromosome
ACE System; a mouse based synthetic chromosome
Protein Production
Validated production of commercially relevant targets including antibodies and cytokines.
Animal Modeling
Successful production of transgenic animals and ex vivo cell therapy modeling.
Genome Engineering
Rational tractable engineering of multigene expression systems, large genomic fragments.
Stem Cell Engineering
Delivery to a variety of stem cell types including adult-derived and embryonic stem cells.
Defense Advance Research Projects Agency (DARPA)
DARPA funded the transition from mouse based synthetic chromosome to human based synthetic chromosome. DARPA is a U.S. government agency that funds cutting-edge, high-risk scientific and technological research. Its mission is to create breakthrough innovations that maintain national security and drive major advances like the internet, GPS, and stealth technology.
02
03
2025
Version 2.0 of a synthetic chromosome: a human based synthetic chromosome (hSynC)
Genome Engineering
Rational tractable engineering of large multigene therapeutic gene products and safety switches.
Stem Cell Engineering
Delivery to a protein manufacturing cell line and pluripotent stem cells.
Animal Modeling
Successful production in ex vivo cell therapy model.
Key Point
Single genetic operating system for a variety of needs.
Built upon over 20 Years Experience to Create
Transformative Synthetic Biology Medicines
Our Genetic Operating System:
01
Early 2000’s
Version 1.0 of a synthetic chromosome
ACE System; a mouse based synthetic chromosome
Early 2000’s
Version 1.0 of a synthetic chromosome
ACE System; a mouse based synthetic chromosome
Protein Production
Validated production of commercially relevant targets including antibodies and cytokines.
Protein Production
Validated production of commercially relevant targets including antibodies and cytokines.
Animal Modeling
Successful production of transgenic animals and ex vivo cell therapy modeling.
Animal Modeling
Successful production of transgenic animals and ex vivo cell therapy modeling.
Genome Engineering
Rational tractable engineering of multigene expression systems, large genomic fragments.
Genome Engineering
Rational tractable engineering of multigene expression systems, large genomic fragments.
Stem Cell Engineering
Delivery to a variety of stem cell types including adult-derived and embryonic stem cells
Stem Cell Engineering
Delivery to a variety of stem cell types including adult-derived and embryonic stem cells
02
Defense Advance Research Projects Agency (DARPA)
DARPA funded the transition from mouse based synthetic chromosome to human based synthetic chromosome DARPA is a U.S. government agency that funds cutting-edge, high-risk scientific and technological research. Its mission is to create breakthrough innovations that maintain national security and drive major advances like the internet, GPS, and stealth technology.
Defense Advance Research Projects Agency (DARPA)
DARPA funded the transition from mouse based synthetic chromosome to human based synthetic chromosome DARPA is a U.S. government agency that funds cutting-edge, high-risk scientific and technological research. Its mission is to create breakthrough innovations that maintain national security and drive major advances like the internet, GPS, and stealth technology.
2025
Version 2.0 of a synthetic chromosome: a human based synthetic chromosome (hSynC)
2025
Version 2.0 of a synthetic chromosome: a human based synthetic chromosome (hSynC)
Genome Engineering
Rational tractable engineering of large multigene therapeutic gene products and safety switches.
Genome Engineering
Rational tractable engineering of large multigene therapeutic gene products and safety switches.
Stem Cell Engineering
Delivery to a protein manufacturing cell line and pluripotent stem cells.
Stem Cell Engineering
Delivery to a protein manufacturing cell line and pluripotent stem cells.
Animal Modeling
Successful production in ex vivo cell therapy model.
Animal Modeling
Successful production in ex vivo cell therapy model.
Key Point
Single genetic operating system for a variety of needs.
Key Point
Single genetic operating system for a variety of needs.
03
About US
Our mission: At CG Bioengineering, we are developing a human synthetic chromosome (hSynC) - Cell Engineering System with the aim of finding cures for people suffering from under-addressed and unaddressed human genetic diseases.
Built upon over 20 Years Experience to Create
Transformative Synthetic Biology Medicines
Our Genetic Operating System:
Early 2000’s
Version 1.0 of a synthetic chromosome
ACE System; a mouse based synthetic chromosome
Early 2000’s
Version 1.0 of a synthetic chromosome
ACE System; a mouse based synthetic chromosome
Protein Production
Validated production of commercially relevant targets including antibodies and cytokines
Protein Production
Validated production of commercially relevant targets including antibodies and cytokines
Animal Modeling
Successful production of transgenic animals and ex vivo cell therapy modeling.
Animal Modeling
Successful production of transgenic animals and ex vivo cell therapy modeling.
Genome Engineering
Rational tractable engineering of multigene expression systems, large genomic fragments
Genome Engineering
Rational tractable engineering of multigene expression systems, large genomic fragments
Stem Cell Engineering
Delivery to a variety of stem cell types including adult-derived and embryonic stem cells
Stem Cell Engineering
Delivery to a variety of stem cell types including adult-derived and embryonic stem cells
01
02
Defense Advance Research Projects Agency (DARPA)
DARPA funded the transition from mouse based synthetic chromosome to human based synthetic chromosome DARPA is a U.S. government agency that funds cutting-edge, high-risk scientific and technological research. Its mission is to create breakthrough innovations that maintain national security and drive major advances like the internet, GPS, and stealth technology.
Defense Advance Research Projects Agency (DARPA)
DARPA funded the transition from mouse based synthetic chromosome to human based synthetic chromosome DARPA is a U.S. government agency that funds cutting-edge, high-risk scientific and technological research. Its mission is to create breakthrough innovations that maintain national security and drive major advances like the internet, GPS, and stealth technology.
2025
Version 2.0 of a synthetic chromosome: a human based synthetic chromosome (hSynC)
2025
Version 2.0 of a synthetic chromosome: a human based synthetic chromosome (hSynC)
Genome Engineering
Rational tractable engineering of large multigene therapeutic gene products and safety switches.
Genome Engineering
Rational tractable engineering of large multigene therapeutic gene products and safety switches.
Stem Cell Engineering
Delivery to a protein manufacturing cell line and pluripotent stem cells.
Stem Cell Engineering
Delivery to a protein manufacturing cell line and pluripotent stem cells.
Animal Modeling
Successful production in ex vivo cell therapy model.
Animal Modeling
Successful production in ex vivo cell therapy model.
Key Point
Single genetic operating system for a variety of needs.
Key Point
Single genetic operating system for a variety of needs.
03
Partnerships
Seeking codevelopment/
license opportunities:
Partnerships form a core component of our strategy, allowing us to access capabilities and resources to advance our hSynC - Cell Engineering technology for cell therapy applications. We are interested in partnering with biopharma companies, academic centers, universities and other relevant organizations.
For inquiries, please contact: aduncan@cgbioengineering.com
Partnering with pharmaceutical, biotechnology, and patient advocacy groups to advance our hSynC technology for cell therapy applications.
Partners
EIRx Biologics Inc: Commercial license for use of the hSynC-Cell Engineering System for the treatment of Duchenne Muscular Dystrophy (DMD)
Goal: overcome current DMD limitations with viral-mediated gene delivery, the hSynC overcomes payload capacity and safety concerns by delivering full dystrophin gene via induced pluripotent stem (iPS) cell.
EIRx Biologics Inc: Commercial license for use of the hSynC-Cell Engineering System for the treatment of Duchenne Muscular Dystrophy (DMD)
Goal: overcome current DMD limitations with viral-mediated gene delivery, the hSynC overcomes payload capacity and safety concerns by delivering full dystrophin gene via induced pluripotent stem (iPS) cell.
The Defense Advanced Research Projects Agency: (DARPA) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military DARPA program encourages research proposals from across academia and industry to develop new platform technologies enabling delivery of therapeutics throughout the body with exceptional efficiency and minimal toxicity.
The Defense Advanced Research Projects Agency: (DARPA) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military DARPA program encourages research proposals from across academia and industry to develop new platform technologies enabling delivery of therapeutics throughout the body with exceptional efficiency and minimal toxicity.
LEADERSHIP
A Team Driven by Science and Innovation
Amy L. Greene
CEO
Dr. Greene was Co-founder and Managing Partner of SynPloid Biotek, LLC, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering. Dr. Greene has a scientific background in synthetic chromosome biology. She served as Manager Intellectual Property and Business Development, Chromos Molecular Systems, Inc. (Vancouver, BC Canada). She previously held an academic appointment as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine. Dr. Greene earned her PhD at the University of Iowa (USA) and did post-doctoral work at the National Institutes of Health.
Amy L. Greene, PhD
Chief Executive Officer
Amy L. Greene
CEO
Dr. Greene was Co-founder and Managing Partner of SynPloid Biotek, LLC, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering. Dr. Greene has a scientific background in synthetic chromosome biology. She served as Manager Intellectual Property and Business Development, Chromos Molecular Systems, Inc. (Vancouver, BC Canada). She previously held an academic appointment as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine. Dr. Greene earned her PhD at the University of Iowa (USA) and did post-doctoral work at the National Institutes of Health.
Amy L. Greene, PhD
Chief Executive Officer
Amy L. Greene
CEO
Dr. Greene was Co-founder and Managing Partner of SynPloid Biotek, LLC, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA) and currently known as CG Bioengineering. Dr. Greene has a scientific background in synthetic chromosome biology. She served as Manager Intellectual Property and Business Development, Chromos Molecular Systems, Inc. (Vancouver, BC Canada). She previously held an academic appointment as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine. Dr. Greene earned her PhD at the University of Iowa (USA) and did post-doctoral work at the National Institutes of Health.
Amy L. Greene, PhD
Chief Executive Officer